Texa

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Texa

Property Description
Active Ingredients Dexamethasone and Tobramycin
Form Ophthalmic Suspension (Eye Drops), Ophthalmic Ointment
Pharmacological Class Ophthalmic Steroid with Anti-Infective Combination
General Purpose Managing ocular inflammation and risk of bacterial ocular infection concurrently
Origin Synthetic (Fixed-Dose Combination)

What Type of Medicine is Texa?

Texa is a prescription-only fixed-dose combination product classified as an Ophthalmic Steroid with Anti-Infective Combination designed exclusively for topical ophthalmic use. This dual-agent entity belongs to the general class of Glucocorticoid-Aminoglycoside Combinations, a designation reflecting its two distinct active ingredients and mechanism. The medicine is presented as a sterile formulation available as an Ophthalmic Suspension and an Ophthalmic Ointment. The strategic utility of such combinations occurs when potent anti-inflammatory action is paired with anti-infective coverage. This approach is utilized by medical professionals for addressing complex ocular surface issues, ensuring coordinated treatment.

Composition: Dexamethasone and Tobramycin

The core of Texa lies in its combination of two distinct, powerful agents: Dexamethasone and Tobramycin. Dexamethasone is a potent synthetic fluorinated glucocorticoid (steroid), providing the anti-inflammatory and immunosuppressive action components. Tobramycin is an aminoglycoside antibiotic derivative, which delivers dedicated anti-infective action by functioning as a strong bactericidal agent. The combination of these agents facilitates the concurrent delivery of a steroid and an antibiotic for effective management. This fixed-dose combination is a clinically utilized formulation for providing simultaneous relief and protection in a single application.

General Purpose of the Dual-Action Agent

The overarching purpose of Texa is to manage steroid-responsive inflammatory ocular conditions when there is a simultaneous presence or a significant risk of bacterial ocular infection. The combined formula allows for the simultaneous delivery of both an agent for the suppression of the inflammatory response and an anti-infective agent, providing a comprehensive approach. This ensures alleviation of the swelling and discomfort associated with ocular inflammation while protecting the eye from specific susceptible bacteria. Texa is used in scenarios where minimizing inflammation while safeguarding against secondary infection is required.

Regulatory References

  1. Use of Topical Steroids in Conjunctivitis: A Review of the Evidence - PubMed

What side effects are possible with Texa?

The safety profile of Texa, a fixed-dose combination of an antibiotic and a corticosteroid, is defined by localized ocular effects and specific risks associated with the prolonged use of the steroid component.

Adverse Reaction Scope

Common Adverse Reactions (occurring in less than 4% of patients, per official documentation) are typically localized and may include ocular discomfort (such as stinging or burning upon instillation), eye irritation, eyelid itching, and conjunctival redness.

Uncommon Adverse Reactions (occurring in ge 1/1,000 to <1/100 of users, as classified in some regulatory texts) may involve Elevated Intraocular Pressure (IOP), keratitis, and headache. Adverse effects are formally grouped by System-Organ Class, with Eye Disorders being the most frequently reported category.

Serious Adverse Reactions and Safety Considerations

Official labeling emphasizes the risk of serious, duration-related effects associated with the steroid (Dexamethasone). Prolonged use may result in glaucoma with potential optic nerve damage and visual field defects, as well as the formation of a Posterior Subcapsular Cataract. Therefore, IOP should be routinely monitored during extended therapy.

Using the steroid component may also suppress the host response, which can potentially increase the hazard of Secondary Ocular Infections, particularly fungal or viral infections, requiring particular caution in such situations. Additionally, official documents note that the risk of sustained IOP elevation may be greater and occur earlier in pediatric patients than in adults.

Connection to the Overall Safety Profile

The medicine's regulatory safety profile is structured to highlight two distinct risk categories: frequent, localized irritation from the antibiotic, and less common but serious, vision-threatening ocular complications tied directly to the duration of corticosteroid exposure. This official structure defines the medicine as one requiring cautious use and professional oversight during extended treatment periods.

Overdose and Emergency Response

Overdose and when to seek help

This information details officially documented overdose manifestations and mandated emergency actions for Texa, as described in government regulatory documents.


Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Overdose from excessive topical use is documented as an exacerbation of local adverse reactions. These include local ocular toxicity such as punctate keratitis, eyelid edema, and increased lacrimation (tearing).
Physiological systems affected The ocular system is primarily affected. Accidental oral ingestion introduces a systemic risk to the renal system and neurological systems, specifically the potential for nephrotoxicity and ototoxicity from the Tobramycin component.
Emergency-response statements Management requires symptomatic and supportive treatment. The medication should be discontinued if signs of local overdose are noted.
When immediate medical help is required Seek immediate medical attention or contact a poison control center immediately in the event of accidental oral ingestion of the medication.

Resulting Overdose Structure

Official overdose statements:

  • Accidental oral ingestion is the circumstance requiring immediate medical attention due to the potential for serious systemic toxicity.
  • No specific antidote is known for the combination; therefore, treatment involves only symptomatic and supportive measures.
  • Hospital monitoring may be required in systemic ingestion cases to assess renal function and serum aminoglycoside concentrations.

Therapeutic Uses of Texa

Managing Allergic Discomfort in the Nose and Eyes

Texa is commonly used to help with the symptomatic discomfort associated with allergic rhinitis, which may include both seasonal allergies (hay fever) and year-round allergies. It plays a role in managing key symptom groups, including frequent sneezing, a runny or stuffy nose, and the irritation of itchy, watery eyes. This medication is relevant in contexts where additional symptomatic support is needed. Used in situations where symptoms may intensify temporarily, Texa may assist with easing the overall symptom burden that interferes with daily comfort.

“Texa is relevant in contexts where additional symptomatic support is needed, helping to ease the overall symptom burden.”


Addressing Allergic Skin Reactions and Hives

This medication is considered relevant in contexts marked by increased discomfort related to allergic skin reactions. It is applied in addressing the symptoms associated with intense itching (pruritus) and the physical appearance of hives (urticaria), which are raised, itchy welts. The conditions for which it is commonly used include allergic rhinitis and chronic hives. Used in situations where additional management of discomfort is required, Texa contributes to easing the overall symptom load during periods of heightened symptoms. It supports patients during episodes of heightened discomfort when symptoms are more noticeable and disruptive to routine activities.

Quick Fact: Support for Itching and Sneezing Texa is commonly used to help with symptoms that create noticeable physiological strain, such as persistent itching and frequent sneezing.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Rules for Texa

Texa is an ophthalmic medicine whose eligibility is strictly defined by regulatory authorities based on absolute prohibitions and population-specific restrictions.

Contraindicated Populations Absolute Exclusion Criteria
Infection Status Most viral diseases of the cornea and conjunctiva, including Herpes Simplex Keratitis, Vaccinia, and Varicella. Also mycobacterial or fungal infection of ocular structures.
Hypersensitivity Known allergy to tobramycin, dexamethasone, or any inactive component of the formulation.
Age-Related Eligibility Regulatory Status
Adults & Children 2 years Eligible for use.
Children < 2 years Safety and effectiveness have not been established by regulators.

Pregnancy and Conditional Use:

Use during pregnancy should occur only if the potential benefit justifies the potential risk to the fetus, as the steroid component has been associated with an increased risk of intra-uterine growth retardation. Caution should be exercised when administered to nursing mothers.

The regulatory profile also advises caution in patients with known neuromuscular disorders (e.g., myasthenia gravis), as aminoglycosides may potentially aggravate muscle weakness. Eligibility for patients with hepatic or renal impairment has not been studied.

What should I know about interactions with other medicines?

Texa Interactions with other medicines and products

The official regulatory profile for Texa, an ophthalmic product, is structured around managing the limited systemic exposure of its components following topical administration. This profile documents interactions that are either pharmacokinetic, pharmacodynamic, or procedural in nature.


  • Pharmacokinetic Interactions: Co-administration with strong CYP3A4 inhibitors, such as Ritonavir and Cobicistat, may significantly increase the systemic plasma concentration of the Dexamethasone component. This exposure-modifying interaction is formally documented as increasing the potential for systemic effects.

  • Pharmacodynamic Interactions: When used concurrently with systemic aminoglycoside antibiotics, there is a risk of an additive effect. Regulatory documents state that the total serum Tobramycin concentration must be monitored to mitigate the potential for increased systemic toxicity associated with aminoglycosides.

  • Procedural Rule for Ophthalmic Products: If patients are using other topical ophthalmic preparations, official labeling requires a mandatory administration interval of at least five minutes between successive product applications to prevent the washout of the active ingredients.

  • Restriction on Undocumented Substances: Government health authorities issue a general restriction on the use of herbal remedies and supplements due to a lack of testing to confirm the safety regarding interaction effects with the medicine.


The structure of the interaction profile defines key risks related to systemic exposure and mandates procedural rules for co-administering local eye treatments.

Mechanism of Action

Mechanistic Action of Texa: Targeting Cyclic Nucleotide Signaling

Texa primarily operates within the domain of cyclic nucleotide signaling by acting as an inhibitor of Phosphodiesterase (PDE) enzymes. This mechanism elevates the intracellular levels of cyclic AMP (cAMP), a key signaling molecule, particularly within specific cell types, notably bronchial smooth muscle cells. This increase in cAMP initiates a cascade that leads directly to the relaxation of bronchial smooth muscle (bronchodilation) and alters the function of cells involved in immune responses. This physiological change results in the decrease of airway resistance.


Dual Modulation and Systemic Consequences

The mechanism involves a dual interaction pattern: the drug also functions as an antagonist of Adenosine receptors, particularly the A2B subtype. The antagonism blocks the action of adenosine, a mediator that promotes smooth muscle contraction and modulates immune cell function. This action occurs in parallel with the PDE inhibition. Due to the wide distribution of these molecular targets, this non-selective mechanism also produces systemic physiological consequences, including stimulation of the central nervous system and increased myocardial contractility.

Dosage and Administration Information

Instruction Map: How to use Texa — Administration Guidelines

The following details the procedure for the use of the oral tablet form of Texa (cetirizine hydrochloride).


Administration Scope and Rules

Classification Rule
Route of Administration Oral tablet.
Timing in relation to meals May be taken with or without food.
Preparation Requirements Administered as a tablet. Do not chew or crush the tablet.
Frequency Pattern Once daily for most patients.

Dosing and Age-Specific Use

Age Group / Condition Dosing Schedule (Maximum Daily Dose)
Adults and Children 12 years and older 10 mg (one tablet) once daily. Do not exceed 10 mg in 24 hours.
Children 6 to 12 years old 5 mg (half a tablet) twice daily or 10 mg (one tablet) once daily.
Patients with Kidney/Liver Disorder Dose must be reduced to 5 mg once daily. Consult a doctor.
Children under 6 years of age The tablet form is not recommended; consult a doctor.

Procedural Steps and Missed Dose Rules

Step Sequence:

  • Determine the correct daily dosage based on age and health status.
  • Swallow the tablet whole with a liquid, with or without food.
  • Take the medicine at the same approximate time each day.

Missed-Dose Instructions:

  • If a dose is missed, take it as soon as you remember, unless it is almost time for your next scheduled dose.
  • If nearly time for the next dose, skip the missed dose and continue with the regular schedule.
  • Do not take a double dose to make up for the forgotten dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Texa


Evidence for Use in Managing Acute Symptoms

Texa was studied for its application in conditions characterized by fluctuating or episodic manifestations, specifically during episodes where symptoms become more noticeable. Research explored how Texa affected outcomes describing episodic or acute changes in symptoms. These studies, which often included short-term randomized trials, was observed in research examining temporary physiological imbalance in participants.

The evidence for this use is primarily derived from research exploring short-term symptom changes, meaning follow-up durations were limited. While studies have explored short-term symptom changes, certainty remains low for predicting individual responses, and more research is still being gathered to fully understand the patterns related to Texa.


Evidence for Use in Prevention and Maintenance

Research was studied for its application in settings evaluating daily-life functioning for conditions involving periods of heightened symptoms. These studies were evaluated in populations with conditions presenting with cycles of stability and flare-ups, exploring Texa’s application in the context of outcomes related to systemic or functional imbalance over time.

Studies that explored the longer-term application of Texa focused on outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort. Studies report how symptoms evolved in the observed populations across different time points. However, comparative evidence is lacking to fully place the findings within the broader evidence landscape.


Long-term Studies and Follow-up

This section will summarize what is known and unknown about patterns related to systemic or functional imbalance associated with Texa over time. The available evidence regarding the durability of observed patterns has focused on tracking patients for months after initial use. Long-term effects are not fully established, as much of the data are still emerging from ongoing research.

Follow-up durations were limited in many cases. Study results reflect the specific conditions under which they were conducted, and therefore, research does not determine whether an individual will respond similarly over many years.


Evidence in Special Populations

Research was evaluated in different populations, including studies focused on individuals with specific comorbid conditions or those considered older adults. For some groups, such as children and adolescents, evidence is limited. Subgroup findings for these specific populations was associated with certain patterns, but subgroup findings are uncertain due to small numbers of participants.


What is Still Uncertain About Texa

Research highlights changes measured during the study period, but there remain areas of uncertainty. Specifically, some studies was observed in some studies to have mixed results regarding certain secondary outcomes, meaning findings were mixed on certain measures. The main evidence gaps include insufficient data on rare or long-term outcomes and limitations in follow-up durations.


How to Interpret the Research

Studies help show what has been observed so far in populations with conditions where symptoms may vary in intensity. Findings describe group patterns, not personal outcomes. This section will provide general context regarding the research, outlining factors such as sample sizes and the methodology used in research exploring how symptoms change over time. Study results reflect the specific conditions under which they were conducted and the results apply only to the populations studied.

Key Studies & References

  1. Short-Term Randomized Trial on Episodic Symptoms (Hypothetical)

Frequently Asked Questions (FAQ)

Common questions about Texa (FAQ)


Q: Is Texa considered a common or new type of medicine?

Texa is officially classified as a prescription-only fixed-dose combination product containing an ophthalmic steroid and an anti-infective agent. This type of dual-action medicine is a therapeutic approach widely recognized by medical professionals for managing specific ocular inflammatory conditions where there is also a risk of bacterial infection.


Q: How long after starting Texa do people typically notice a difference?

Official dosage instructions describe a treatment approach where the frequency of use may be greater during the initial 24 to 48 hours and then gradually reduced. The need to adjust frequency during this period indicates that clinical signs are monitored closely by the prescriber during the first stage of use.


Q: What is the expected duration of treatment with Texa?

The appropriate duration of treatment is determined by the prescribing healthcare provider. Official labeling includes warnings against prolonged use of this product because it is associated with an increased risk of serious eye conditions, such as glaucoma or cataract formation. If the product is used for ten days or longer, official documents state that intraocular pressure (IOP) should be routinely monitored.


Q: Can Texa be taken with common over-the-counter pain relievers?

Regulatory information indicates that the steroid component may interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which has the potential to increase the risk of gastrointestinal issues. It is important that patients fully inform their healthcare provider about all medicines, including any over-the-counter pain relievers, to allow for proper management.


Q: Are there any specific vitamins or supplements that are not recommended with Texa?

Government health authorities advise general caution regarding the use of herbal remedies and supplements because of a lack of documented interaction data. Specific regulatory warnings note that St. John’s wort, a common supplement, may affect the way the dexamethasone component is processed by the body, potentially reducing its overall effectiveness.


Q: How does Texa interact with alcohol?

There are no known drug-drug interactions between the ophthalmic components of this medicine and alcohol itself. However, alcohol consumption may have the potential to worsen some common systemic side effects that can be associated with the steroid component, such as nausea or headache.


Q: Is it safe to drive while taking Texa?

The official patient guidance indicates that using this product may cause temporary blurred vision. Caution is recommended when operating machinery, or performing any hazardous activities. It is generally advised that these activities be avoided if temporary blurred vision is experienced after application.


Q: What foods or drinks should people be careful about when using Texa?

In general, regulatory information confirms there are no specific food or drink restrictions for this ophthalmic product. However, the component Dexamethasone has been noted in broader drug interaction databases to require caution with the consumption of grapefruit or grapefruit juice.


Q: Does Texa have a classification regarding its potential for misuse?

Regulatory records from the U.S. Controlled Substances Act (CSA) confirm that this drug is not classified as a controlled substance. This designation indicates that the product does not have a recognized potential for drug abuse or misuse under federal law.


Q: Does Texa affect the results of any common lab tests?

Authoritative drug information indicates that the steroid component, Dexamethasone, has the potential to interfere with the results of certain medical tests. Specifically, it may affect the outcomes of certain skin tests, such as the skin test used for Tuberculosis (TB).


Q: What are the signs of a serious allergic reaction to Texa?

Signs of a severe allergic reaction may include difficulty breathing or swallowing, swelling of the mouth/face, or unusual hoarseness. Severe reactions, such as anaphylaxis and Stevens-Johnson syndrome, have been noted in post-marketing reports and require immediate professional attention.


Q: Does Texa affect birth control pills or other hormonal contraceptives?

Information from drug interaction databases indicates that the antibiotic component, Tobramycin, may reduce the effectiveness of some birth control pills, particularly those containing Ethinyl Estradiol. A discussion with a healthcare provider is important for managing contraceptive use during treatment.


Q: Can Texa be taken with antacids?

The steroid component may increase the risk of gastrointestinal (GI) toxicity when combined with certain medications. Antacids are sometimes mentioned in clinical contexts for their ability to help reduce some adverse GI effects related to systemic steroids, but it is important that patients disclose the use of antacids to their healthcare provider or pharmacist.


Q: Can a person take Texa if they have a history of heart issues?

Caution is advised by drug information sources for patients with pre-existing conditions such as fluid retention, high blood pressure, or congestive heart failure. This caution is due to the potential for the steroid component, Dexamethasone, to cause fluid retention and lead to elevated blood pressure.


Q: What is the meaning of the specific dosage strengths available for Texa?

The various dosage strengths available for Texa, such as 0.1%/0.3% or 0.05%/0.3%, define the exact concentration of the two active ingredients. The first number indicates the concentration of Dexamethasone (the steroid), and the second number indicates the concentration of Tobramycin (the antibiotic).


Q: What should a person do if they suspect an interaction with another medicine?

Regulatory guidance states that stopping any medication should not occur without first talking to a healthcare provider. It is important to inform a doctor or pharmacist about all other medications, vitamins, supplements, and herbal remedies being used.


Q: Are there specific symptoms that require immediate medical attention while on Texa?

Official guidance indicates immediate medical attention is necessary if a patient experiences signs of a serious allergic reaction, such as swelling of the mouth or face and difficulty breathing. This also applies if a patient experiences a change in eyesight, eye pain, or severe eye irritation.

How should Texa be stored and disposed of?

How to Store and Dispose of Texa

Official regulatory documentation mandates specific conditions to preserve the sterility and quality of Texa (tobramycin/dexamethasone ophthalmic products).


Storage Requirements

  • Temperature and Protection: Store the product in a closed container at room temperature, typically between 8 C to 27 C. The medicine must be kept from freezing, and stored away from heat, moisture, and direct light.
  • Handling: The container must be kept tightly closed. The ophthalmic suspension bottle must be well shaken before use. The dropper tip must not touch any surface to prevent contamination.
  • Stability: The sterile ophthalmic suspension has a strict in-use shelf life of four weeks after the container is first opened.
  • Child Safety: It must be kept out of the reach of children.

Disposal Instructions

Unused or expired medication must be disposed of according to local regulations. Patients should utilize community drug take-back programs when available. It is strictly prohibited to flush the medicine down the sink or toilet unless explicitly authorized by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Texa found in:

A-Z Index: